MAPK3 and breast carcinoma: We suggest that the SASP stimulates breast cancer cell proliferation through activation of the MEK-ERK1/2 pathway, and that simvastatin suppresses this SASP-induced activation in breast cancer cells (as schematically shown in Fig. 5d).